![]() Q School of Chemical and Biotechnology, SASTRA University, Thanjavur, Tamil Nadu, India r University of Florence, Florence, Italy H Department of Pharmaceutical Sciences, College of Pharmacy, Larkin Health Sciences Institute, Miami, FL, United States i Department of Urology, University of Miami, Miller School of Medicine, Miami, FL, United States j Miami Veterans Administration Medical Center, Miami, FL, United States k Department of Environmental Science, Dalhousie University, Canada ' Department of Microbiology and Immunology, Dalhousie University, Canada m Laboratory of Inflammatory Mediators, State University of West Paraná, UNIOESTE, Paraná, Brazil n Department ofBioMedical Sciences, School of Medicine, Creighton University, Omaha, NE, United StatesĠĝepartment of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC, United States p Huntsman Cancer Institute and Department of Internal Medicine, University of Utah, Salt Lake City, UT, United States HelferichE, Xujuan YangEĪ Sanus Biosciences, San Diego, CA, United States b Institute of Cancer Sciences, University of Glasgow, UKĬ Physics Department, School of Applied Mathematics and Physical Sciences, National Technical University of Athens, Athens, Greece d Department of Pathology, Wayne State Univeristy, Karmanos Cancer Center, USA e Department of Experimental and Clinical Medicine, University of Florence, Italyį Department of Biology, College of Science, United Arab Emirates University, AlAin, United Arab Emirates g Faculty ofScience, Cairo University, Cairo, Egypt Shantha Kumaraz, Somaira NowsheenC, Sulma I. Hofsetho, Luigi Ricciardiellox, Maria Rosa Ciriolov, Neetu Singhy, Richard L. Vasantha Rupasinghes, Hiromasa Fujiit, Kanya Honoki1, Kapil Mehtau, Katia Aquilanov, Leroy Lowew *, Lorne J. Stafforinip, Dipita Bhaktaq, Elena Niccolair, Gunjan Guhaq, H.P. Lokeshwarij, Brendan Gruekl, Carolina Panism, Chandra S. Azmid, Amedeo Amedeie, Amr Aminf g, Anupam Bishayeeh, Bal L. Seminars in Cancer Biology xxx (2015) xxx-xxxĪ multi-targeted approach to suppress tumor-promoting inflammation^Ībbas K. Future translational work will need to assess the resulting synergies of rationally designed antiinflammatory mixtures (employing low-toxicity constituents), and then combine this with similar approaches targeting the most important pathways across the range of cancer hallmark phenotypes. Specifically, macrophage migration inhibitory factor, cyclooxygenase-2, transcription factor nuclear factor-κB, tumor necrosis factor alpha, inducible nitric oxide synthase, protein kinase B, and CXC chemokines are reviewed as important antiinflammatory targets while curcumin, resveratrol, epigallocatechin gallate, genistein, lycopene, and anthocyanins are reviewed as low-cost, low toxicity means by which these targets might all be reached simultaneously. We discuss the relationship between tumor-promoting inflammation and cancer as part of a larger effort to develop a broad-spectrum therapeutic approach aimed at a wide range of targets to address this heterogeneity. While efforts have been made to combine targeted therapies, significant levels of toxicity have stymied efforts to effectively treat cancer with multi-drug combinations using currently approved therapeutics. Georgakilas, Amedeo Amedei, Amr Amin, et al.Ĭancers harbor significant genetic heterogeneity and patterns of relapse following many therapies are due to evolved resistance to treatment. Abstract of research paper on Clinical medicine, author of scientific article - Abbas K.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |